Related Experiment Video
Updated: Aug 28, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Stereotactic body radiation therapy for hepatocellular carcinoma larger than 5 cm: a systematic review and
Jiaoling He1,2, Xiurong Wang1,2, Tingfang Zuo3
1The School of Basic Medical Sciences, Fujian Medical University, No. 1 Xuefu North Road, University Town, Fuzhou, China.
Purpose:
The efficacy of stereotactic body radiation therapy (SBRT) for large (≥ 5 cm) hepatocellular carcinoma (HCC) remains unclear.
Materials And Methods:
This systematic review and meta-analysis (PROSPERO: CRD420261295276) searched six databases (Embase, PubMed, Scopus, Web of Science, Cochrane Library, and Clinical Trial databases) and included eleven studies (424 patients) evaluating SBRT for large HCC up to May 31, 2026.
Results:
The pooled 1- and 2-year local control rates were 81% (95% confidence interval [CI], 66-90%) and 69% (95% CI 48-84%), respectively, and the corresponding overall survival rates were 60% (95% CI 55-66%) and 37% (95% CI 30-45%). Mean/median age < 65 years was a favorable factor for 2-year overall survival (P < 0.05). Severe liver toxicity (grade ≥ 3) is rare. SBRT provides effective local control and overall survival with acceptable toxicity for large HCC.
Conclusion:
These findings support SBRT as a viable option for patients with HCC ≥ 5 cm, although further prospective studies are warranted.
